查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
胞外体诊断和治疗的全球市场：按产品类型、产品/服务、来源和应用分类 - 预测（截至 2032 年）
市场调查报告书
商品编码
1493074

胞外体诊断和治疗的全球市场：按产品类型、产品/服务、来源和应用分类 - 预测（截至 2032 年）

Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032
出版日期: | 出版商: MarketsandMarkets | 英文 251 Pages | 订单完成后即时交付

价格
简介目录

全球胞外体诊断市场规模预计将从 2024 年的 5,900 万美元增至 2029 年的 23.47 亿美元，复合年增长率为 108.9%。

然而，预计基于胞外体的候选治疗药物将在 2029 年后上市。因此，胞外体诊断和治疗市场预计将产生 5,900 万美元，到 2024 年将达到 68.48 亿美元，到 2032 年复合年增长率将达到 81.2%。临床试验的增加预计将支持该领域的成长。基于胞外体的疗法利用细胞释放的囊泡来传递治疗有效负荷。这些囊泡具有诸如增加运输材料的生物利用度以及穿过血脑障壁等生物屏障的能力等优点。儘管有这些好处，胞外体疗法尚未获得监管部门的核准。这是由于标准化胞外体分离和精製方法、扩大生产规模、确保安全和监管流程等挑战所造成的。 Regeneus Ltd（澳洲）、CUREXSYS（德国）和 Direct Biologics LLC（美国）等公司是该领域的主要企业，专注于开发基于胞外体的临床适应症治疗方法。

调查范围
调查年份 2022-2032
基准年 2023年
预测期 2024-2032
单元 100万美元
部分 按类型、按产品/服务、按应用、按原产地、按最终用户、按地区
目标区域 北美、欧洲、亚太等地区

“预计在预测期内，家电和服务领域将以最快的速度增长。”

在外胞外体诊断和治疗中，胞外体表征是透过流式细胞技术、奈米颗粒追踪分析和超速离心精确进行的。胞外体表征和改进服务的需求不断增长预计将推动市场成长。活跃于胞外体体诊断和治疗市场的一些市场参与企业也利用专利和专有技术提供端到端的胞外体服务，包括工程、表征和精製。这些公司从商业性角度提供支援服务，目标是从血液、尿液和唾液等潜在诊断样本中大规模製造和分析胞外体。

“到 2023 年，尿液衍生细分市场将占据最大的市场份额。”

基于尿液样本的诊断测试的快速商业化预计将推动市场发展。泌尿系统细胞释放的尿液胞外体为诊断和监测肾臟疾病提供了新途径。胞外体的独特特征，例如它们保护其分子货物免遭降解和污染的能力，使它们成为肾功能障碍和结构损伤生物标记的主要候选者。非侵入性尿液收集方法以及尿液胞外体的稳定性和充足性证明了早期疾病检测和诊断的潜力。

“肿瘤学预计将成为市场上的主导应用领域。”

对癌症治疗的日益关注预计将推动市场成长。胞外体在癌症治疗中也发挥重要作用，作为靶向癌细胞并递送药物、 RNA干扰分子、免疫调节剂等的治疗货物的载体。美国德克萨斯州德州大学 MD 安德森癌症中心正在研究补充 KrasG12D siRNA（iExosomes）的间质基质细胞来源的胞外体治疗具有 KrasG12D 突变的胰臟癌患者的最佳剂量和疗效。临床试验（NCT03608631）。儘管取得了这些进展，但胞外体分离技术的优化和肿瘤治疗的有效实施等挑战预计将阻碍预测期内的市场成长。

本报告研究和分析了全球胞外体诊断和治疗市场，提供主要驱动和限制因素、竞争格局和未来趋势等资讯。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

  • 胞外体诊断与治疗市场概况
  • 北美胞外体诊断和治疗市场：按类型和国家划分（2029 年）
  • 北美胞外体诊断与治疗市场：按类型（2029年和2032年）

第五章市场概况

  • 介绍
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 供应链分析
  • 价值链分析
  • 专利分析
    • 专利分析：胞外体诊断
    • 专利分析：胞外体疗法
  • 监管环境
    • 监管场景
    • 监管机构、政府机构和其他组织
  • 波特五力分析
  • 主要相关利益者和采购标准
  • 投资金筹措场景
  • 胞外体疗法：开发与製造过程
    • 胞外体分离
    • 胞外体表征和品管
    • 胞外体的产生
  • 管道分析
    • 管线分析：胞外体疗法
    • 管道分析：胞外体诊断
  • 定价分析
    • 主要企业平均售价趋势：依产品分类
    • 平均销售价格趋势：按地区
  • 生态系分析
  • 影响客户业务的趋势/干扰
  • 主要会议及活动
  • 技术分析
    • 主要技术
    • 互补技术
    • 邻近技术

第六章胞外体诊断与治疗市场：依类型

  • 介绍
  • 胞外体诊断
  • 胞外体疗法

第七章胞外体诊断市场：依产品及服务分类

  • 介绍
  • 套件/试剂
  • 设备/服务

第八章胞外体诊断与治疗市场：依来源分类

  • 介绍
  • 干细胞
  • 血浆
  • 尿
  • 其他样品

第九章胞外体诊断市场：依应用分类

  • 介绍
  • 癌症
  • 皮肤病
  • 肌肉骨骼疾病
  • 心血管疾病
  • 其他用途

第 10 章胞外体诊断与治疗市场：依最终使用者分类

  • 介绍
  • 医院
  • 诊所、医生环境

第十一章胞外体诊断与治疗市场：按地区

  • 介绍
  • 北美洲
    • 经济衰退对北美的影响
    • 美国
    • 加拿大
  • 欧洲
    • 经济衰退对欧洲的影响
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 经济衰退对亚太地区的影响
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 其他地区

第十二章竞争格局

  • 概述
  • 主要企业策略/主要企业
  • 收益分析
  • 市场占有率分析
  • 企业评价矩阵：主要企业（2023年）
  • 竞争评估矩阵：Start-Ups/小型企业 (2023)
  • 竞争场景

第十三章 公司简介

  • 主要企业
    • BIO-TECHNE
    • NANOFCM INC.
    • SYSTEM BIOSCIENCES, LLC.
    • CAPITAL BIOSCIENCES, INC.
    • AMSBIO
    • INOVIQ
    • DIRECT BIOLOGICS LLC
    • REGENEUS LTD
    • CUREXSYS
    • AEGLE THERAPEUTICS
  • 其他公司
    • MERCY BIOANALYTICS
    • NANOSOMIX, INC.
    • EXONOX BIOSCIENCES, INC.
    • MULTIMMUNE GMBH
    • CAPRICOR THERAPEUTICS, INC.
    • EVOX THERAPEUTICS
    • ILIAS BIOLOGICS INC.
    • RION
    • EXOGENUS THERAPEUTICS
    • EVERZOM
    • KIMERA LABS

第十四章附录

简介目录
Product Code: BT 9039

The exosome diagnostics market is projected to grow from USD 59 million in 2024 to USD 2,347 million by 2029 at a CAGR of 108.9%. However, the candidates for exosome-based therapeutics are expected to be launched in the market from 2029 onwards. Thus, collectively exosome diagnostics and therapeutics market is expected to generate USD 59 million by 2024 and projected to reach USD 6,848 million in 2032 at a CAGR of 81.2%. Increasing number of clinical trials is expected to support the segment growth. Exosome-based therapies utilize vesicles released by cells to deliver therapeutic payloads. These vesicles offer advantages such as enhanced cargo bioavailability and the ability to cross biological barriers such as the blood-brain barrier. Despite these benefits, exosome therapies have not yet received regulatory approval. This is attributed to the challenges of standardizing exosome isolation and purification methods, scaling production, safety assurance, and regulatory processes. Companies such as Regeneus Ltd (Australia), CUREXSYS (Germany), and Direct Biologics LLC (US) are the key players in this segment that are focused on developing exosome-based therapeutics for clinical indications.

Scope of the Report
Years Considered for the Study2022-2032
Base Year2023
Forecast Period2024-2032
Units ConsideredValue (USD) Million
SegmentsBy Type, Product & Service, Source, Application, End User, And Region
Regions coveredNorth America, Europe, Asia Pacific, and ROW

"Instruments & services segment is expected to grow at the fastest pace during the forecast period."

Exosome characterization is done precisely through flow cytometry, nanoparticle tracking analysis, and ultracentrifugation in exosome diagnoses and treatments. The rising demand for exosome characterization & enrichment services is expected to support market growth. Some market players operating in the exosome diagnostics and therapeutics market also use their patented/proprietary technologies to offer end-to-end exosome services, including engineering, characterization, and purification. These players provide support services from a commercial viewpoint, targeted toward scalable exosome manufacturing and analysis from potential diagnostic samples such as blood, urine, and saliva.

"The urine source segment accounted for the largest share in the exosome diagnostics and therapeutics market in 2023."

Rapid commercialization of urine sample-based diagnostic tests is set to drive market. Urinary exosomes, released by cells in the urine system, represent an emerging route for diagnosing and monitoring renal disorders. Their distinct characteristics, such as the capacity to shield their molecular cargo from degradation and contamination, make them primary candidates for renal dysfunction and structural injury biomarkers. The non-invasive method of urine collection and the stability and sufficiency of urinary exosomes highlight its potential for early disease detection and diagnosis.

"Cancer is expected to emerge as the dominant application segment in the exosome therapeutics market."

Growing focus on oncology therapeutics is expected to propel the market growth. Exosomes also play a critical role in cancer therapy as carriers of therapeutic cargo, delivering drugs, RNA interference molecules, or immunomodulatory agents to target cancer cells. The University of Texas MD Anderson Cancer Center in Texas (US) is conducting clinical trials (NCT03608631) to study the optimal dosage effects and effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation. Despite these developments, challenges such as optimizing the exosome isolation technology and ensuring efficient delivery of therapeutic cargo to tumors are expected to hinder market growth during the forecast period.

North America dominates the global exosome diagnostics and therapeutics market throughout the forecast period.

The exosome diagnostics and therapeutics market is segmented into four regions: North America, Europe, the Asia Pacific (APAC), and the Rest of the World. As of April 2024, only one exosome-based diagnostic product has been approved and is available in the US. The US has thus emerged as a key revenue source for the global exosome diagnostics and therapeutics market, in turn making North America the dominant region in the market.

Breakdown of supply-side primary interviews by company type, designation, and region:

  • By Respondent: Supply Side (70%), Demand side (30%)
  • By Designation: C-level (55%), Director-level (20%), and Others (25%)
  • By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)

List of Companies Profiled in the Report

  • Bio-Techne (US)
  • NanoFCM Inc. (UK)
  • System Biosciences, LLC. (US)
  • Capital Biosciences, Inc. (US)
  • AMSBIO (UK)
  • INOVIQ (Australia)
  • Direct Biologics LLC (US)
  • Regeneus Ltd (Australia)
  • CUREXSYS (Germany)
  • Aegle Therapeutics (US)
  • Mercy Bioanalytics (US)
  • multimmune GmbH (Germany)
  • RION (US)
  • Exogenus Therapeutics (Portugal)
  • Everzom (France)
  • Kimera Labs (US)
  • NanoSomiX, Inc. (US)
  • Exonox Biosciences, Inc. (Taiwan)
  • Capricor Therapeutics, Inc. (US)
  • Evox Therapeutics (US)
  • ILIAS Biologics Inc. (Korea)

Research Coverage

This report studies the exosome diagnostics and therapeutics market based on type, product & service, source, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total exosome diagnostics and therapeutics market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

.

  • Market Drivers: The key factors driving the overall market growth emerging potential of exosome-based liquid biopsy, increasing collaborations & commercialization initiatives, and growing outsourcing of exosome manufacturing activities.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the exosome diagnostics and therapeutics market.
  • Market Penetration: Comprehensive information on exosome diagnostics and therapeutics offered by the top 21 players in the market. The report analyzes the exosome diagnostics and therapeutics market by type, product & service, application, source, end user, and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/types of exosome diagnostics and therapeutics across key geographic regions.
  • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the exosome diagnostics and therapeutics market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the exosome diagnostics and therapeutics market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 MARKET SEGMENTATION
    • 1.3.2 REGIONS COVERED
    • FIGURE 2 REGIONAL SEGMENTATION
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 3 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 4 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
    • FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
    • 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
    • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • 2.3 MARKET GROWTH RATE PROJECTIONS
    • FIGURE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
    • FIGURE 9 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.4 DATA TRIANGULATION AND MARKET BREAKDOWN
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ASSESSMENT ANALYSIS
    • TABLE 1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: RISK IMPACT ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
    • TABLE 3 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 4 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION)
    • FIGURE 12 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY PRODUCT & SERVICE, 2029 VS. 2032 (USD MILLION)
    • FIGURE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2029 VS. 2032 (USD MILLION)
    • FIGURE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY APPLICATION, 2029 VS. 2032 (USD MILLION)
    • FIGURE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2029 VS. 2032 (USD MILLION)
    • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET OVERVIEW
    • FIGURE 17 EMERGING POTENTIAL OF EXOSOME-BASED LIQUID BIOPSY TO DRIVE MARKET
  • 4.2 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE AND COUNTRY (2029)
    • FIGURE 18 EXOSOME THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2029
  • 4.3 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION)
    • FIGURE 19 EXOSOME DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 20 EXOSOME DIAGNOSTICS AND THERAPEUTIC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Emerging potential of exosome-based liquid biopsy
      • 5.2.1.2 Increasing initiatives for product commercialization
      • 5.2.1.3 Growing outsourcing of exosome-based manufacturing activities
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Technical complexities associated with exosome isolation
      • 5.2.2.2 Stringent regulatory requirements
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing adoption of exosome biomarkers for personalized medicine
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Inadequate protocols for exosome development & production
  • 5.3 SUPPLY CHAIN ANALYSIS
    • FIGURE 21 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 22 VALUE CHAIN ANALYSIS: MANUFACTURING PROCESSES AND REGULATORY INVESTMENTS ADD MAXIMUM VALUE
  • 5.5 PATENT ANALYSIS
    • 5.5.1 PATENT ANALYSIS: EXOSOME DIAGNOSTICS
    • FIGURE 23 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, JANUARY 2013-OCTOBER 2023
    • FIGURE 24 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, BY JURISDICTION
    • 5.5.2 PATENT ANALYSIS: EXOSOME THERAPEUTICS
    • FIGURE 25 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, JANUARY 2013-OCTOBER 2023
    • FIGURE 26 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, BY JURISDICTION
  • 5.6 REGULATORY LANDSCAPE
    • 5.6.1 REGULATORY SCENARIO
      • 5.6.1.1 North America
        • 5.6.1.1.1 US
        • 5.6.1.1.2 Canada
      • 5.6.1.2 Europe
        • 5.6.1.2.1 Germany
        • 5.6.1.2.2 Spain
      • 5.6.1.3 Asia Pacific
        • 5.6.1.3.1 China
        • 5.6.1.3.2 Japan
        • 5.6.1.3.3 South Korea
    • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.7 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 7 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.7.1 THREAT OF NEW ENTRANTS
    • 5.7.2 THREAT OF SUBSTITUTES
    • 5.7.3 BARGAINING POWER OF SUPPLIERS
    • 5.7.4 BARGAINING POWER OF BUYERS
    • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EXOSOME DIAGNOSTICS & THERAPEUTICS
    • 5.8.2 BUYING CRITERIA FOR END USERS
    • FIGURE 28 KEY BUYING CRITERIA FOR END USERS
  • 5.9 INVESTMENT AND FUNDING SCENARIO
    • TABLE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: INVESTMENT & FUNDING SCENARIO
  • 5.10 EXOSOME THERAPEUTICS: DEVELOPMENT & MANUFACTURING PROCESS
    • 5.10.1 EXOSOME ISOLATION
    • TABLE 9 EXOSOME ISOLATION TECHNIQUES
    • 5.10.2 EXOSOME CHARACTERIZATION AND QC
    • 5.10.3 EXOSOME PRODUCTION
  • 5.11 PIPELINE ANALYSIS
    • FIGURE 29 EXOSOME PIPELINE, BY INTERVENTION TYPE
    • FIGURE 30 EXOSOME PIPELINE, BY PHASE
    • 5.11.1 PIPELINE ANALYSIS: EXOSOME THERAPEUTICS
    • FIGURE 31 EXOSOME THERAPEUTICS PIPELINE, BY PHASE
    • FIGURE 32 EXOSOME THERAPEUTICS PIPELINE, BY REGION
    • 5.11.2 PIPELINE ANALYSIS: EXOSOME DIAGNOSTICS
    • FIGURE 33 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY APPLICATION
    • FIGURE 34 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY COUNTRY
    • TABLE 10 PIPELINE PRODUCTS FOR EXOSOME DIAGNOSTICS
    • TABLE 11 PIPELINE PRODUCTS FOR EXOSOME THERAPEUTICS
  • 5.12 PRICING ANALYSIS
    • 5.12.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
    • TABLE 12 AVERAGE SELLING PRICE OF EXOSOME DIAGNOSTIC PRODUCTS, BY KEY PLAYER
    • 5.12.2 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.13 ECOSYSTEM ANALYSIS
    • FIGURE 35 EXOSOME DIAGNOSTICS AND THERAPEUTICS: ECOSYSTEM MAP
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 36 REVENUE SHIFT AND NEW POCKETS
  • 5.15 KEY CONFERENCES & EVENTS
    • TABLE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2024-2025)
  • 5.16 TECHNOLOGY ANALYSIS
    • 5.16.1 KEY TECHNOLOGIES
    • TABLE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: KEY TECHNOLOGIES
    • 5.16.2 COMPLIMENTARY TECHNOLOGIES
    • 5.16.3 ADJACENT TECHNOLOGIES

6 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 16 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
  • 6.2 EXOSOME DIAGNOSTICS
    • 6.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION & DIAGNOSIS TO PROPEL MARKET
    • TABLE 17 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 18 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 19 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 20 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 21 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 22 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 23 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 24 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)
  • 6.3 EXOSOME THERAPEUTICS
    • 6.3.1 INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH
    • TABLE 25 EXOSOME THERAPEUTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 26 EXOSOME THERAPEUTICS MARKET, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 27 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 28 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 29 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 30 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 31 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)

7 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 7.1 INTRODUCTION
    • TABLE 33 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 34 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2030-2032 (USD MILLION)
  • 7.2 KITS & REAGENTS
    • 7.2.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTIC KITS TO DRIVE MARKET
    • TABLE 35 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 36 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 38 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 39 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 40 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 41 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030-2032 (USD MILLION)
  • 7.3 INSTRUMENTS & SERVICES
    • 7.3.1 RISING FOCUS ON OUTSOURCING EXOSOME PREPARATION ACTIVITIES TO SUPPORT MARKET GROWTH
    • TABLE 43 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 44 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2030-2032 (USD MILLION)

8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE

  • 8.1 INTRODUCTION
    • TABLE 45 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 46 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
  • 8.2 STEM CELLS
    • 8.2.1 GROWING UPTAKE OF MSC-DERIVED EXOSOMES IN CELLULAR PROCESSES TO DRIVE MARKET
    • TABLE 47 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 48 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 49 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 50 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 51 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 52 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 54 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030-2032 (USD MILLION)
  • 8.3 BLOOD & BLOOD PLASMA
    • 8.3.1 ABILITY TO ENHANCE TREATMENT RESPONSE AND DISEASE DIAGNOSIS TO BOOST DEMAND
    • TABLE 55 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 56 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 57 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 58 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 59 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 60 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 61 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 62 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030-2032 (USD MILLION)
  • 8.4 URINE
    • 8.4.1 RAPID COMMERCIALIZATION OF URINE SAMPLE-BASED DIAGNOSTIC TESTS TO DRIVE MARKET
    • TABLE 63 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 64 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 65 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 66 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 67 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 68 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030-2032 (USD MILLION)
  • 8.5 OTHER SAMPLES
    • TABLE 71 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 72 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 73 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 74 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 75 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 76 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 77 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 78 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030-2032 (USD MILLION)

9 EXOSOME THERAPEUTICS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 79 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 80 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
  • 9.2 CANCER
    • 9.2.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET
    • TABLE 81 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 82 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 83 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 84 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 85 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 86 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 87 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 88 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030-2032 (USD MILLION)
  • 9.3 DERMATOLOGICAL DISEASES
    • 9.3.1 INCREASING R&D ACTIVITIES FOR WOUND HEALING AND REGENERATIVE MEDICINE TO DRIVE MARKET
    • TABLE 89 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 90 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 91 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 92 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 93 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 94 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 95 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 96 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030-2032 (USD MILLION)
  • 9.4 MUSCULOSKELETAL DISORDERS
    • 9.4.1 RISING INCIDENCE OF OSTEOARTHRITIS TO SUPPORT MARKET GROWTH
    • TABLE 97 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 98 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 99 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 100 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 101 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 102 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 103 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 104 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030-2032 (USD MILLION)
  • 9.5 CARDIOVASCULAR DISEASES
    • 9.5.1 GROWING FOCUS ON TARGETED THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH
    • TABLE 105 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 106 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 107 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 108 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 109 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 110 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 112 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030-2032 (USD MILLION)
  • 9.6 OTHER APPLICATIONS
    • TABLE 113 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 114 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 115 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 116 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 117 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 118 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 120 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030-2032 (USD MILLION)

10 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 121 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 122 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
  • 10.2 HOSPITALS
    • 10.2.1 GROWING COLLABORATIONS WITH PHARMA & BIOPHARMA COMPANIES TO DRIVE MARKET
    • TABLE 123 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 124 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 125 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 126 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 127 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 128 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 129 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 130 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030-2032 (USD MILLION)
  • 10.3 CLINICS AND PHYSICIAN SETTINGS
    • 10.3.1 RISING ADOPTION OF LIQUID BIOPSY KITS TO SUPPORT MARKET GROWTH
    • TABLE 131 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 132 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2030-2032 (USD MILLION)
    • TABLE 133 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 134 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 135 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 136 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030-2032 (USD MILLION)

11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 139 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 140 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2030-2032 (USD MILLION)
  • 11.2 NORTH AMERICA
    • 11.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT
    • TABLE 141 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 142 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 143 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 144 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 145 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 146 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 147 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 148 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 149 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 150 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.2.2 US
      • 11.2.2.1 Rising R&D initiatives for development of exosomes to drive market
    • TABLE 151 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 152 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 153 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 154 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 155 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 156 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 157 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 158 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.2.3 CANADA
      • 11.2.3.1 Increasing funding initiatives for genomic-based treatments to support market growth
    • TABLE 159 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 160 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 161 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 162 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 163 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 164 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 165 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 166 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
  • 11.3 EUROPE
    • 11.3.1 EUROPE: RECESSION IMPACT
    • FIGURE 38 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT
    • TABLE 167 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 168 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 169 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 170 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 171 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 172 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 173 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 174 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 175 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 176 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.3.2 GERMANY
      • 11.3.2.1 Commercialization of pipeline candidates to propel market
    • TABLE 177 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 178 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 179 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 180 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 181 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 182 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 183 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 184 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.3.3 UK
      • 11.3.3.1 Rising growth in life sciences research to drive market
    • TABLE 185 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 186 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 187 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 188 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 189 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 190 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 191 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 192 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.3.4 FRANCE
      • 11.3.4.1 Presence of emerging players for exosome preparation to fuel market
    • TABLE 193 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 194 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 195 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 196 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 197 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 198 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 199 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 200 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.3.5 ITALY
      • 11.3.5.1 Rising growth in biotech sector to boost demand
    • TABLE 201 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 202 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 203 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 204 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 205 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 206 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 207 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 208 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.3.6 SPAIN
      • 11.3.6.1 Increasing initiatives for exosome research to support market growth
    • TABLE 209 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 210 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 211 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 212 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 213 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 214 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 215 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 216 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 217 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 218 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 219 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 220 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 221 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 222 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 223 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 224 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 225 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 226 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030-2032 (USD MILLION)
    • TABLE 227 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 228 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 229 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 230 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 231 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 232 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 233 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 234 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Increasing healthcare expenditure to propel market
    • TABLE 235 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 236 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 237 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 238 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 239 JAPAN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 240 JAPAN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 241 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 242 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.4.3 CHINA
      • 11.4.3.1 Rising incidence of chronic diseases to drive market
    • TABLE 243 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 244 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 245 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 246 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 247 CHINA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 248 CHINA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 249 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 250 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.4.4 INDIA
      • 11.4.4.1 Increasing pool of start-ups and rising funding investments to fuel market
    • TABLE 251 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 252 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 253 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 254 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 255 INDIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 256 INDIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 257 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 258 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.4.5 SOUTH KOREA
      • 11.4.5.1 Rising developments by leading market players to boost demand
    • TABLE 259 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 260 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 261 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 262 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 263 SOUTH KOREA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 264 SOUTH KOREA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 265 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 266 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.4.6 AUSTRALIA
      • 11.4.6.1 Increasing adoption of novel therapeutics to support market growth
    • TABLE 267 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 268 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 269 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 270 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 271 AUSTRALIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 272 AUSTRALIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 273 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 274 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.4.7 REST OF ASIA PACIFIC
    • TABLE 275 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 276 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 277 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 278 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 279 REST OF ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 280 REST OF ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 281 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 282 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
  • 11.5 REST OF THE WORLD
    • 11.5.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET
    • TABLE 283 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 284 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030-2032 (USD MILLION)
    • TABLE 285 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 286 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030-2032 (USD MILLION)
    • TABLE 287 REST OF THE WORLD: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 288 REST OF THE WORLD: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030-2032 (USD MILLION)
    • TABLE 289 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 290 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030-2032 (USD MILLION)
    • 11.5.2 REST OF THE WORLD: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 39 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS (2021-2024)
  • 12.3 REVENUE ANALYSIS
    • FIGURE 40 REVENUE ANALYSIS OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, 2022-2032
  • 12.4 MARKET SHARE ANALYSIS
    • FIGURE 41 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SHARE ANALYSIS (2023)
    • TABLE 291 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DEGREE OF COMPETITION
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 42 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 12.5.5.1 Overall company footprint
    • TABLE 292 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: OVERALL COMPANY FOOTPRINT
      • 12.5.5.2 Regional footprint
    • TABLE 293 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: REGIONAL FOOTPRINT
      • 12.5.5.3 Product & service footprint
    • TABLE 294 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PRODUCT & SERVICE FOOTPRINT
      • 12.5.5.4 Type footprint
    • TABLE 295 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: TYPE FOOTPRINT
      • 12.5.5.5 Application footprint
    • TABLE 296 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: APPLICATION FOOTPRINT
  • 12.6 COMPETITIVE EVALUATION MATRIX: START-UPS/SMES, 2023
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 STARTING BLOCKS
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 RESPONSIVE COMPANIES
    • FIGURE 43 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
    • 12.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
    • TABLE 297 EXOSOME THERAPEUTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 12.7 COMPETITIVE SCENARIO
    • 12.7.1 DEALS
    • TABLE 298 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DEALS, JANUARY 2021-APRIL 2024
    • 12.7.2 OTHER DEVELOPMENTS
    • TABLE 299 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2024

13 COMPANY PROFILES

  • (Business overview, Products/Solutions/Services offered, Recent developments & MnM View)**
  • 13.1 KEY PLAYERS
    • 13.1.1 BIO-TECHNE
    • TABLE 300 BIO-TECHNE: COMPANY OVERVIEW
    • FIGURE 44 BIO-TECHNE: COMPANY SNAPSHOT (2023)
    • TABLE 301 BIO-TECHNE: PRODUCTS/SERVICES OFFERED
    • TABLE 302 BIO-TECHNE: DEALS
    • TABLE 303 BIO-TECHNE: OTHER DEVELOPMENTS
    • 13.1.2 NANOFCM INC.
    • TABLE 304 NANOFCM INC.: COMPANY OVERVIEW
    • TABLE 305 NANOFCM INC.: PRODUCTS/SERVICES OFFERED
    • 13.1.3 SYSTEM BIOSCIENCES, LLC.
    • TABLE 306 SYSTEM BIOSCIENCES, LLC.: COMPANY OVERVIEW
    • TABLE 307 SYSTEM BIOSCIENCES, LLC.: PRODUCTS/SERVICES OFFERED
    • 13.1.4 CAPITAL BIOSCIENCES, INC.
    • TABLE 308 CAPITAL BIOSCIENCES, INC.: COMPANY OVERVIEW
    • TABLE 309 CAPITAL BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED
    • 13.1.5 AMSBIO
    • TABLE 310 AMSBIO: COMPANY OVERVIEW
    • TABLE 311 AMSBIO: PRODUCTS/SERVICES OFFERED
    • 13.1.6 INOVIQ
    • TABLE 312 INOVIQ: COMPANY OVERVIEW
    • FIGURE 45 INOVIQ: COMPANY SNAPSHOT (2023)
    • TABLE 313 INOVIQ: PRODUCTS/SERVICES OFFERED
    • TABLE 314 INOVIQ: DEALS
    • 13.1.7 DIRECT BIOLOGICS LLC
    • TABLE 315 DIRECT BIOLOGICS: COMPANY OVERVIEW
    • TABLE 316 DIRECT BIOLOGICS: PRODUCTS/SERVICES OFFERED
    • TABLE 317 DIRECT BIOLOGICS: REGULATORY APPROVALS
    • TABLE 318 DIRECT BIOLOGICS: OTHER DEVELOPMENTS
    • 13.1.8 REGENEUS LTD
    • TABLE 319 REGENEUS LTD: COMPANY OVERVIEW
    • TABLE 320 REGENEUS LTD: PRODUCTS/SERVICES OFFERED
    • 13.1.9 CUREXSYS
    • TABLE 321 CUREXSYS: COMPANY OVERVIEW
    • TABLE 322 CUREXSYS: PRODUCTS/SERVICES OFFERED
    • 13.1.10 AEGLE THERAPEUTICS
    • TABLE 323 AEGLE THERAPEUTICS: COMPANY OVERVIEW
    • TABLE 324 AEGLE THERAPEUTICS: PRODUCTS/SERVICES OFFERED
  • *Details on Business overview, Products/Solutions/Services offered, Recent developments & MnM View might not be captured in case of unlisted companies.
  • 13.2 OTHER PLAYERS
    • 13.2.1 MERCY BIOANALYTICS
    • TABLE 325 MERCY BIOANALYTICS: COMPANY OVERVIEW
    • 13.2.2 NANOSOMIX, INC.
    • TABLE 326 NANOSOMIX, INC.: COMPANY OVERVIEW
    • 13.2.3 EXONOX BIOSCIENCES, INC.
    • TABLE 327 EXONOX BIOSCIENCES, INC.: COMPANY OVERVIEW
    • 13.2.4 MULTIMMUNE GMBH
    • TABLE 328 MULTIMMUNE GMBH: COMPANY OVERVIEW
    • 13.2.5 CAPRICOR THERAPEUTICS, INC.
    • TABLE 329 CAPRICOR THERAPEUTICS, INC.: COMPANY OVERVIEW
    • 13.2.6 EVOX THERAPEUTICS
    • TABLE 330 EVOX THERAPEUTICS: COMPANY OVERVIEW
    • 13.2.7 ILIAS BIOLOGICS INC.
    • TABLE 331 ILIAS BIOLOGICS, INC.: COMPANY OVERVIEW
    • 13.2.8 RION
    • TABLE 332 RION: COMPANY OVERVIEW
    • 13.2.9 EXOGENUS THERAPEUTICS
    • TABLE 333 EXOGENUS THERAPEUTICS: COMPANY OVERVIEW
    • 13.2.10 EVERZOM
    • TABLE 334 EVERZOM: COMPANY OVERVIEW
    • 13.2.11 KIMERA LABS
    • TABLE 335 KIMERA LABS: COMPANY OVERVIEW

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS